4Q13
Apo Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant with a glucocorticoid receptor-interacting protein 1 NR box II peptide
Summary for 4Q13
Entry DOI | 10.2210/pdb4q13/pdb |
Related | 4PXM 4PY1 |
Descriptor | Estrogen receptor, Glucocorticoid receptor-interacting protein 1 NR box II peptide (3 entities in total) |
Functional Keywords | metastatic breast cancer, activating point mutation, drug resistance, serm resistance, alpha helix, nuclear hormone receptor, hormone binding protein-peptide complex, hormone binding protein/peptide |
Biological source | Homo sapiens (human) More |
Total number of polymer chains | 4 |
Total formula weight | 62631.76 |
Authors | Fanning, S.W.,Panchamukhi, S.,Greene, G.L. (deposition date: 2014-04-02, release date: 2015-04-08, Last modification date: 2024-02-28) |
Primary citation | Fanning, S.W.,Mayne, C.G.,Dharmarajan, V.,Carlson, K.E.,Martin, T.A.,Novick, S.J.,Toy, W.,Green, B.,Panchamukhi, S.,Katzenellenbogen, B.S.,Tajkhorshid, E.,Griffin, P.R.,Shen, Y.,Chandarlapaty, S.,Katzenellenbogen, J.A.,Greene, G.L. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife, 5:-, 2016 Cited by PubMed: 26836308DOI: 10.7554/eLife.12792 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.24 Å) |
Structure validation
Download full validation report